Article

Validation of the FROM-16 in Family Members of Patients Receiving Advanced Therapy Medicinal Product (ATMP)

2024-06-06

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold>: Outcome-based pricing models which consider domains of value not previously considered in healthcare, such as societal outcomes, are of increasing interest for healthcare systems. Societal outcomes can include family-reported outcome measures (FROMs), which measure the impact of disease upon the patient’s family members. The FROM-16 is a generic and easy-to-use fam...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c3db53ef-2b30-5f4c-8508-5ec6064a6ae1
DOI: 10.21203/rs.3.rs-4534055/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Validation of the FROM-16 in Family Members of Patients Receiving Advanced Therapy Medicinal Product (ATMP)DOI 10.21203/rs.3.rs-4534055/v1Read

Feasibility Study Protocol: Investigating Family Reported Outcome Measures (FROMs) in the Estimation of Societal Value of Advanced Therapeutic Medicinal Products (ATMPs)Semantic proximity Read

Feasibility Study Protocol: Investigating Family Reported Outcome Measures (FROMs) in the Estimation of Societal Value of Advanced Therapy Medicinal Products (ATMPs)Semantic proximity Read

Development and psychometric testing of EPAT-16: A short and valid measure for patient-centeredness from the patient’s perspectiveSemantic proximity Read

Content validity, face validity and comprehensiveness of generic quality-of-life measures in adults and children with rare genetic conditions and their carers: a think aloud qualitative studySemantic proximity Read

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read

Quality of life drives patients' preferences for secondary findings from genomic sequencing.Semantic proximity Read

Assessing Side-Effect Bother, Burden, and Tolerability: A Qualitative Study Exploring the Content Validity of the Functional Assessment of Cancer Therapy – Item GP5Semantic proximity Read

Patient Perspective—Where Does the Value for Money of a Treatment Really Lie?Semantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Generic Patient-Reported Outcomes and Outcome Measures: A Systematic Review Study ProtocolSemantic proximity Read

Enhancing participation in the collection of patient-reported outcome and experience measures: Insights and recommendations from a mixed-methods studySemantic proximity Read

Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity Read